3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

Abstract:

:Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any change in tumor size is evident, FDG-PET may fail to distinguish between residual tumor and inflammation and between complete response and partial response with substantial residual tumor burden. PET with the nucleoside analogue 3'-deoxy-3'-(18)F-fluorothymidine (FLT) is more accurate than FDG-PET in visualizing early changes in tumor proliferation. In a recent study in experimental models of esophageal cancer, FLT-PET was more accurate than FDG-PET in detecting early changes in proliferation following docetaxel and radiation therapy in human SEG-1 cells and mouse SEG-1 xenografts, including having a much stronger correlation with histologic findings. Clinical studies are needed to determine if FLT-PET can distinguish among degrees of response to neoadjuvant chemoradiation in patients with esophageal cancer. The ability to visualize tumor cell proliferation may also contribute to the ability to improve precision delivery of radiation therapy.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Chao KS

doi

10.1053/j.seminoncol.2007.01.002

subject

Has Abstract

pub_date

2007-04-01 00:00:00

pages

S31-6

issue

2 Suppl 1

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(07)00018-8

journal_volume

34

pub_type

杂志文章
  • Metastatic breast cancer: preliminary results with oral hormonal therapy.

    abstract::Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

    更新日期:1985-12-01 00:00:00

  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • Molecular biology of upper gastrointestinal malignancies.

    abstract::While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.04.019

    authors: Lin J,Beerm DG

    更新日期:2004-08-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Management of early and locally advanced cervical cancer.

    abstract::Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.12.007

    authors: Barbera L,Thomas G

    更新日期:2009-04-01 00:00:00

  • Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.

    abstract::This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Greco FA,Hainsworth JD

    更新日期:1994-10-01 00:00:00

  • 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue. Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with le...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90251-9

    authors: Seitz JF

    更新日期:2001-02-01 00:00:00

  • Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.

    abstract::The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.08.006

    authors: Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

    更新日期:2012-10-01 00:00:00

  • Pathological and molecular assessment of sentinel lymph nodes in solid tumors.

    abstract::Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.32894

    authors: Krag DN,Weaver DL

    更新日期:2002-06-01 00:00:00

  • Immunotherapeutic strategies for high-risk bladder cancer.

    abstract::Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.12.004

    authors: Sharma P,Old LJ,Allison JP

    更新日期:2007-04-01 00:00:00

  • In vitro data supporting interferon plus cytotoxic agent combinations.

    abstract::The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the pres...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Von Hoff DD

    更新日期:1991-10-01 00:00:00

  • Single-agent gemcitabine in non-small cell lung cancer: the French experience.

    abstract::Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Le Chevalier T,Gottfried M

    更新日期:1997-04-01 00:00:00

  • Single agents in the second-line treatment of non-small cell lung cancer.

    abstract::The options available to patients with advanced non-small cell lung cancer (NSCLC) resistant or refractory to first-line chemotherapy are very limited. The older-generation drugs (etoposide, vindesine, epirubicin, and cisplatin) that are active against previously untreated NSCLC do not achieve a response rate greater ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Belani CP

    更新日期:1998-06-01 00:00:00

  • Gemcitabine combined with docetaxel in metastatic breast cancer.

    abstract::The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2003.37270

    authors: Fumoleau P

    更新日期:2003-04-01 00:00:00

  • Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

    abstract::The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kosmidis PA,Samantas E,Fountzilas G,Pavlidis N,Apostolopoulou F,Skarlos D

    更新日期:1994-06-01 00:00:00

  • The etiology of renal-cell carcinoma.

    abstract::Experimental renal-cell carcinoma can be induced by many different chemical carcinogens; dimethyl nitrosoamine has been most studied. The disease so induced in experimental animals closely resembles the spontaneous disease in man in histopathology, course, and other characteristics. Two agents that are probably etiolo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Outzen HC,Maguire HC Jr

    更新日期:1983-12-01 00:00:00

  • Defining the clinical diagnosis of inflammatory breast cancer.

    abstract::Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.11.010

    authors: Singletary SE,Cristofanilli M

    更新日期:2008-02-01 00:00:00

  • Paclitaxel pharmacokinetics and pharmacodynamics.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kearns CM,Gianni L,Egorin MJ

    更新日期:1995-06-01 00:00:00

  • Is there a place for "dose-dense" weekly schedules of the taxoids?

    abstract::The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Löffler TM

    更新日期:1998-10-01 00:00:00

  • Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.

    abstract::Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00359-2

    authors: Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

    更新日期:2003-10-01 00:00:00

  • Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy.

    abstract::Metastatic cancers during pregnancy have historically been associated with dismal outcomes, with greater rates of tumor progression in part because of diminished treatment alternatives. Immunotherapy with T-cell checkpoint inhibitors has significantly impacted the survival of several metastatic tumors. However, given ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2018.03.003

    authors: Burotto M,Gormaz JG,Samtani S,Valls N,Silva R,Rojas C,Portiño S,de la Jara C

    更新日期:2018-06-01 00:00:00

  • Practical considerations in the evaluation and management of adrenocortical cancer.

    abstract::Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.10.011

    authors: Balasubramaniam S,Fojo T

    更新日期:2010-12-01 00:00:00

  • Management of borderline tumors of the ovary: state of the art.

    abstract::Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tropé C,Kaern J

    更新日期:1998-06-01 00:00:00

  • Intrahepatic arterial infusion of chemotherapy: clinical results.

    abstract::Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31680

    authors: Dizon DS,Kemeny NE

    更新日期:2002-04-01 00:00:00

  • Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

    abstract::To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2002.37360

    authors: Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

    更新日期:2002-12-01 00:00:00

  • Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.

    abstract::The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.026

    authors: Pinzone MR,Berretta M,Cacopardo B,Nunnari G

    更新日期:2015-04-01 00:00:00

  • Therapy of superficial bladder cancer.

    abstract::Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Nseyo UO,Lamm DL

    更新日期:1996-10-01 00:00:00

  • Ethical and legal aspects of cancer genetic testing.

    abstract::As a result of the increasing effectiveness of cancer screening and preventive interventions, ethical issues, as well as legal liabilities, are increasingly associated with cancer genetic testing. These issues include the possible "duty to warn" relatives of inherited cancer risk, the appropriateness of testing of chi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.07.007

    authors: Offit K,Thom P

    更新日期:2007-10-01 00:00:00

  • Review of regional therapy of liver metastases in colorectal cancer.

    abstract::Hepatic metastases are a major cause of mortality in patients with colorectal carcinoma. The rationale for regional therapy is presented. The randomized studies are reviewed and they demonstrated a significantly higher response rate with hepatic arterial therapy versus systemic therapy. Survival information is difficu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny N

    更新日期:1992-04-01 00:00:00

  • Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.

    abstract::A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

    更新日期:1997-12-01 00:00:00